Table 1.
Ongoing clinical trials testing anti-IL-1 drugs, either alone or in combination, in cancer therapy.
| Therapy | Target | Tumor Type | Recruitment Status | Development status | ClinicalTrial.gov Identifier | Sponsor | Start Date | Estimated Completition Date |
|---|---|---|---|---|---|---|---|---|
| Anakinra + Everolimus | IL-1 Ra + anti mTOR | Neoplasm | Active, not recruiting | Phase 1 | NCT01624766 | M.D. Anderson Cancer Center | June, 2012 | June, 2020 |
| Anakinra + Chemo | IL-1 Ra + anti mTOR | Pancreatic Adenocarcinoma | Active, not recruiting | Early Phase 1 | NCT02550327 | Baylor Research Institute | January, 2016 | August, 2023 |
| Anakinra + JCARH125 | IL-1 Ra + CAR T-cells | Multiple Myeloma | Recruiting | Phase 2 | NCT03430011 | Juno Therapeutics | March, 2023 | March, 2023 |
| Anakinra | IL-1 Ra | Multiple Myeloma | Active, not recruiting | Phase 2 | NCT03233776 | Radboud University | May, 2019 | June, 2020 |
| Anakinra | IL-1 Ra | Multiple Myeloma | Recruiting | Phase 2 | NCT04099901 | Radboud University | October, 2020 | October, 2022 |
| Anakinra + Axicabtagene Ciloleucel | IL-1 Ra + CAR T-cells | Neoplasm, Large B-Cell Lymphoma | Not yet recruiting | Phase 1,2 | NCT04432506 | M.D. Anderson Cancer Center | July, 2020 | January, 2025 |
| Anakinra + Axicabtagene Ciloleucel | IL-1 Ra + CAR T-cells | B-Cell Non-Hodgkin Lymphoma | Not yet recruiting | Phase 2 | NCT04359784 | Fred Hutchinson Cancer Research Center | August, 2020 | December, 2021 |
| Anakinra + Axicabtagene Ciloleucel | IL-1 Ra + CAR T-cells | Non-Hodgkin Lymphoma | Not yet recruiting | Phase 2 | NCT04150913 | Marcela V. Maus, M.D.;Ph.D. | July, 2020 | November, 2024 |
| Anakinra | IL-1 Ra | B-Cell Lymphoma and Non-Hodgkin Lymphoma | Recruiting | Phase 2 | NCT04148430 | Memorial Sloan Kettering Cancer Center | October, 2019 | October, 2022 |
| Anakinra + Axicabtagene Ciloleucel | IL-1 Ra + CAR T-cells | Large B-Cell Lymphoma | Recruiting | Phase 2 | NCT04205838 | Jonsson Comprehensive Cancer Center | March, 2020 | December, 2022 |
| Canakinumab | mAb anti IL-1β | Non-small Cell Lung Cancer | Recruiting | Phase 3 | NCT03447769 | Novartis Pharmaceuticals | March, 2018 | January, 2027 |
| Canakinumab + Spartalizumab + LAG525 | mAb anti IL-1β + mAb anti PD-1+ mAb anti LAG-3 | Triple Negative Breast Cancer | Recruiting | Phase 1 | NCT03742349 | Novartis Pharmaceuticals | January, 2019 | January, 2022 |
| Anakinra +/− Pembrolizumab | mAb anti IL-1β +/− mAb anti PDL-1 | Non-small Cell Lung Cancer | Recruiting | Phase 2 | NCT03968419 | Novartis Pharmaceuticals | November, 2019 | January, 2022 |
| Anakinra + Pembrolizumab + Chemo | mAb anti IL-1β +/− mAb anti PDL-1 | Non-small Cell Lung Cancer | Active, not recruiting | Phase 3 | NCT03631199 | Novartis Pharmaceuticals | December, 2018 | September, 2022 |
| Canakinumab + PDR001 | mAb anti IL-1β + mAb anti PD-1 | Triple Negative Breast Cancer and NSCLC | Active, not recruiting | Phase 1 | NCT02900664 | Novartis Pharmaceuticals | August, 2016 | August, 2020 |
| Canakinumab + Spartalizumab | mAb anti IL-1β + mAb anti PD-1 | Renal Cell Carcinoma | Recruiting | Early Phase 1 | NCT04028245 | Charles G. Drake | August, 2019 | December, 2021 |
| Canakinumab | mAb anti IL-1β | Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Not yet recruiting | Phase 2 | NCT04239157 | M.D. Anderson Cancer Center | June, 2020 | December, 2021 |
| Canakinumab + PDR001 + Chemo | mAb anti IL-1β + mAb anti PD-1 | Non-small Cell Lung Cancer | Active, not recruiting | Phase 1 | NCT03064854 | Novartis Pharmaceuticals | May, 2017 | December, 2021 |
| Canakinumab + Spartalizumab | mAb anti IL-1β + mAb anti PD-1 | Melanoma | Recruiting | Phase 2 | NCT03484923 | Novartis Pharmaceuticals | September, 2018 | June, 2022 |
| Canakinumab + Chemo | mAb anti IL-1β | Non-small Cell Lung Cancer | Active, not recruiting | Phase 3 | NCT03626545 | Novartis Pharmaceuticals | January, 2019 | March, 2022 |
| Xilonix + Chemo | mAb anti IL-1α | Pancreatic cancer | Active, not recruiting | Phase 1 | NCT03207724 | Andrew Hendifar, MD | October, 2017 | December, 2020 |
| CAN04 + Pembrolizumab | mAb anti IL1RAP+mAb anti PD-1 | Non-Small-Cell Lung, Urothelial CarcinomaMalignant Melanoma, Head and Neck Squamous Cell Carcinoma | Not yet recruiting | Phase 1 | NCT04452214 | Cantargia AB | September, 2020 | January, 2022 |
| CAN04 + Chemo | mAb anti IL1RAP | Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer | Recruiting | Phase 1/2 | NCT03267316 | Cantargia AB | September, 2017 | June, 2021 |